CIBA CORNING TO AUTOMATE TRITON DIAGNOSTICS' CANCER ASSAYS for use with Ciba's ACS:180 automated, random access chemiluminescent immunoassay system. On Jan. 14, Ciba Corning announced that it acquired Triton Diagnostics, whose products include manual, nonisotopic cancer assays. The Triton manual products include tests for c-erbB-2, "an oncogene clinically associated with breast cancer prognosis and treatment," and urinary gonadatropin peptide, which is "potentially useful in the management of ovarian cancer," Ciba Corning says. These tests are sold commercially overseas and for research use in the U.S. In addition to the manual assays for research use, Triton manufactures the MAK-6 monoclonal anti-cytokeratin cocktail. The firm's only FDA-approved product, the MAK-6 distinguishes epithelial tumors from non-epithelial tumors that are similar in histological appearance. The acquisition of the Triton assays will expand Ciba Corning's ongoing effort to develop cancer assays for the automated ACS:180 system. Automated assays under development by Ciba Corning include tests for prostate-specific antigen, alpha-fetoprotein and carcinoembryonic antigen; the firm is marketing some of the products outside the U.S. Ciba Corning maintains that "bringing full automation capability to cancer testing will significantly reduce the laboratory costs associated with these tests." Triton Diagnostics was a subsidiary of Shell Oil; the petrochemical giant had sold off the pharmaceutical and R&D portion of Triton (Triton Biosciences) in 1990, retaining the diagnostics business ("The Gray Sheet" Sept. 24, 1990, In Brief). Renamed by Ciba Corning as Triton Laboratories, the former Shell subsidiary will be operated as "a fully integrated unit" of Ciba Corning. Triton's 47 employees will continue to work at its facility in Alameda, California.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.
Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
